Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in HR+/HER2- advanced or metastatic breast cancer
NCT07459738Phase 2Not yet recruiting
- Sponsor
- Henlius
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
Phase 2, randomised, open-label trial of HLX43 in breast cancer (2 arms), sponsored by Henlius. Primary endpoints: Objective Response Rate at 24 weeks and Progression-Free Survival at 5 years. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
HLX43
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07459738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07459738.